|
EU must learn from Covid-19 to improve crisis preparedness and response for the future |
Medicines for Europe |
09 Nov 2021 |
Health & Consumers |
|
EU must bolster biosimilar medicines policy to increase equity of access and bring much needed savings to healthcare budgets |
Medicines for Europe |
25 May 2023 |
Health & Consumers |
|
EU must address barriers to continuous off-patent innovation and grasp opportunity for patients and healthcare |
Medicines for Europe |
23 Feb 2021 |
Health & Consumers |
|
EU manufacturers call for urgent reforms to achieve reciprocity and a level-playing field in public procurement |
Medicines for Europe |
30 Sep 2019 |
Health & Consumers |
|
EU Industrial strategy should be key to improving medicines supply chains |
Medicines for Europe |
17 May 2021 |
Health & Consumers |
|
EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply |
Medicines for Europe |
17 Mar 2021 |
Health & Consumers |
|
EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed |
Medicines for Europe |
15 Jan 2021 |
Health & Consumers |
|
EU can do more for patients with smart use of biosimilar medicines |
Medicines for Europe |
29 Apr 2022 |
Health & Consumers |
|
EU can do more for equitable access to medicines |
Medicines for Europe |
13 Jan 2023 |
Health & Consumers |
|
Energy Council (TTE) – Medicines for Europe Open letter to European Energy Ministers and responsible European Commissioners on inflation and energy costs impacting the supply of essential generic medicines |
Medicines for Europe |
28 Sep 2022 |
Health & Consumers |
|
EMA/HMA share definitive EU-wide position on biosimilar medicines interchangeability |
Medicines for Europe |
20 Sep 2022 |
Health & Consumers |
|
EMA clarifies no scientific evidence to deter use of ibuprofen to manage coronavirus symptoms |
Medicines for Europe |
18 Mar 2020 |
Health & Consumers |
|
Electronic product information: new report shows it is time to move from principles to action |
Medicines for Europe |
25 Feb 2022 |
Health & Consumers |
|
Efficient use of pharmacovigilance data essential for patient safety |
Medicines for Europe |
30 Jan 2019 |
Health & Consumers |
|
EBA and Medicines for Europe signed a memorandum of agreement to accelerate Ukraine's integration into the EU pharmaceutical market |
Medicines for Europe |
22 Jun 2023 |
Health & Consumers |
|
Driving local excellence, delivering European results |
Medicines for Europe |
06 Nov 2018 |
Health & Consumers |
|
Decisive action on medicines shortages should be included in pharmaceutical and industrial strategies |
Medicines for Europe |
18 Sep 2020 |
Health & Consumers |
|
Crucial European Parliament vote vastly improves SPC manufacturing waiver |
Medicines for Europe |
24 Jan 2019 |
Health & Consumers |
|
COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy |
Medicines for Europe |
09 Jul 2020 |
Health & Consumers |
|
Court decision on Supplementary Protection Certificate (SPC) manufacturing waiver risks undermining its use |
Medicines for Europe |
18 Jan 2024 |
InfoSociety |
|
Comprehensive SPC manufacturing waiver key for patient access to medicines, jobs and growth in Europe |
Medicines for Europe |
28 May 2018 |
Health & Consumers, Social Europe & Jobs |
|
Competition policy essential for access to medicines |
Medicines for Europe |
29 Jan 2019 |
Health & Consumers |
|
Commission study highlights market framework conditions are main driver for medicines shortages |
Medicines for Europe |
10 Dec 2021 |
Health & Consumers |
|
Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs |
Medicines for Europe |
18 Oct 2017 |
Health & Consumers |
|
CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court |
Medicines for Europe |
20 Sep 2018 |
Health & Consumers |
|
Central & Eastern European patients have inequitable access to medicines for life-threatening conditions |
Medicines for Europe |
25 Apr 2022 |
Health & Consumers |
|
Brexit - Life Science Industry Joint Position Paper |
Medicines for Europe |
14 Dec 2017 |
Health & Consumers, UK in Europe |
|
Biosimilar Medicines: essential for sustainable access to medicines |
Medicines for Europe |
27 Apr 2018 |
Health & Consumers |
|
Biosimilar medicines: competition, sustainability and early* access on the agenda of DG GROW stakeholder workshop |
Medicines for Europe |
30 Oct 2019 |
Health & Consumers |
|
Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe |
Medicines for Europe |
09 May 2017 |
Health & Consumers |
